GENMAB A/S business relationships
Companies named in GENMAB A/S’s 20-F filed 2026-02-17, and public companies whose annual reports name GENMAB A/S. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 10 / 100
- AI adoption
- 0 / 100
Named in GENMAB A/S’s annual report 15
“In 2025 , royalties from Johnson & Johnson (" J&J "), legal entity Janssen Biotech, Inc., related to daratumumab” SEC filing
“We receive royalties from J&J, Novartis, Roche and Partner Therapeutics based on net” SEC filing
“worldwide by Novartis under a license agreement between Genmab and Novartis.” SEC filing
“license agreements with us, or in the case of TEPEZZ A, under a sublicense from Roche and BIZENGRI, which is marketed” SEC filing
“with Gilead (Gilead Collaboration Agreement) to research and develop trispecific T-cell engaging antibody product” SEC filing
“pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining” SEC filing
“Our partners Pfizer and AbbVie are” SEC filing
“created by Genmab under a collaboration with Roche and development and commercialization of the product is currently” SEC filing
“These include products that are being developed in collaboration with L undbeck, Novo Nordisk and” SEC filing
“Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab” SEC filing
“Seagen and Zai Lab announced an exclusive collaboration and license agreement for the development and” SEC filing
“In June 2020, we entered into a Collaboration and License Agreement with AbbVie to jointly develop and” SEC filing
“pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining” SEC filing
“Merus exclusively licensed to Partner Therapeutics Inc. (" P artner” SEC filing
“License Agreement") with Partner Therapeutics, Inc ("PTx").” SEC filing
Companies whose annual reports name GENMAB A/S 5
“Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.” SEC filing
“(c) Tivdak is commercialized in collaboration with Genmab A/S.” SEC filing
“Side Letter No. 5 to License and Collaboration Agreement by and between Registrant and Genmab A/S, dated August 12,” SEC filing
“...wo revenue-generating strategic collaboration agreements in place with Moderna and BMS, after the termination of the collaboration agreement IMA401 ("BMS IMA401") and Allo ("BMS Allo"), as well as the termination of the collaboration agreement with Genmab A/S, Copenhagen /Denmark ("Genmab") in 2024.” SEC filing
“In May 2021, we entered into a License and Collaboration Agreement with Genmab A/S to evaluate Genmab antibodies in combination with our immune-stimulating linker-payload technology for the discovery and development of next-generation ISACs.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.